-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
【Pharmaceutical Network Policies and Regulations】Traditional Chinese medicine is a treasure of Chinese civilization and plays an important role
in maintaining human health.
It is worth noting that talent is the first resource for the development of traditional Chinese medicine, and it also plays a supporting and guaranteeing role
in it.
It is understood that in the past 10 years, the scale of China's traditional Chinese medicine talent team has continued to grow, and the number of practicing (assistant) physicians in the category of traditional Chinese medicine has increased steadily year by year, accounting for 14.
1% of the total number of practicing (assistant) physicians from 14.
1% to 17.
1%, reaching 731,700; the number of practicing (assistant) physicians in the category of traditional Chinese medicine per 10,000 population has reached 5.
18, an increase of 91.
14%
over 10 years ago.
However, compared with the chemical pharmaceutical and biopharmaceutical industries, there is still a relative shortage
of high-level talents in traditional Chinese medicine.
Data show that in 2021, the average number of R&D personnel in 445 A-share pharmaceutical and biological listed companies will be 18.
5%, and the average number of R&D personnel will be 499.
In terms of subdivision, the number of R&D personnel in listed companies of chemical pharmaceuticals, biological products and traditional Chinese medicine accounted for an average of 19.
3%, 19.
5% and 10.
5%, and the average number of R&D personnel was 413, 319 and 305
.
From these two indicators, the average combing of R&D personnel and the proportion of total employees of listed Chinese medicine companies are lower than the average level of A-share pharmaceutical biology, and lower than the two major sectors
of chemical pharmaceuticals and biological preparations.
The industry believes that at the moment when the country vigorously develops the traditional Chinese medicine industry, cultivating and cultivating a team of high-quality Chinese medicine talents has become a shortcoming that needs to be made up urgently for the inheritance and innovation of traditional Chinese medicine in China
.
In fact, in recent years, the state has been trying to expand the supply of grassroots talents in traditional Chinese medicine and promote the flow
of talents to the grassroots.
For example, in order to enhance the supporting and guaranteeing role of talents in the development of traditional Chinese medicine, the "Opinions on Promoting the Inheritance and Innovation and Development of Traditional Chinese Medicine" was issued in January 2020, which is the first time that the State Administration of Traditional Chinese Medicine has taken the lead in formulating this policy document for the systematic deployment of traditional Chinese medicine talents, and put forward a series of policy measures
to strengthen the work of traditional Chinese medicine talents 。 At the beginning of 2021, the state issued the "Several Policies and Measures on Accelerating the Development of Chinese Medicine Characteristics", which consolidates the foundation of Chinese medicine talents and strengthens the construction of talents with Chinese medicine characteristics, and clearly proposes to improve the overall level of Chinese medicine education, adhere to the development of Chinese medicine teacher education, strengthen the evaluation and incentive of Chinese medicine talents, and other measures
。 In June this year, the State Administration of Traditional Chinese Medicine, the Ministry of Education, the Ministry of Human Resources and Social Security, and the National Health Commission jointly issued the Opinions on Strengthening the Work of Traditional Chinese Medicine Talents in the New Era; It puts forward six key tasks, such as accelerating the training and gathering of high-level talents in traditional Chinese medicine and consolidating the team of grassroots Chinese medicine talents, so as to provide strong talent support
for the revitalization and development of traditional Chinese medicine.
At the end of October, the State Administration of Traditional Chinese Medicine also issued the "14th Five-Year Plan for the Development of Chinese Medicine Talents", which clearly proposed to accelerate the promotion of Chinese medicine talents and build a team of
high-quality Chinese medicine talents.
The plan points out that Chinese medicine has ushered in a rare development opportunity in the world's unprecedented major changes in a century, and it is urgent to accelerate the revitalization and development of
traditional Chinese medicine.
It is understood that the plan focuses on the specific tasks of the construction of various talent teams, and establishes a clearer goal
of talent classification and training.
At present, with the help of national policies, Yunnan Province, Heilongjiang Province, Jiangxi Province, Hunan Province and other places have also issued documents, clearly stating that they will consolidate the talent base of
traditional Chinese medicine.
The industry expects that under the background of the national vigorous promotion of the construction of medical talent teams in key fields, the improvement of the quality of Chinese medicine talent training, and the deepening of the reform of the system and mechanism for the development of Chinese medicine talents, the scale, structural layout, talent quality and use efficiency of Chinese medicine talents in China will continue to be enhanced, and further promote the inheritance and innovation of
traditional Chinese medicine.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.